gmp
gmp

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Connect Biopharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Medicon Valley Inhalation Symposium

              Participation Not Confirmed

              Update your events

              Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis

              Contact the Supplier

              Lead Product(s): CBP-201

              Therapeutic Area: Dermatology Product Name: CBP-201

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: RA Capital Management

              Deal Size: $115.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing August 24, 2020

              Details:

              The company plans to use the proceeds to support the ongoing Phase 2 clinical trial for CBP-201; Phase 2 trials of CBP-307; expand the CBP-201 clinical development program into additional indications; and to support planned Phase 3 trials of CBP-201 and CBP-307.

              Connect Biopharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Medicon Valley Inhalation Symposium

              Participation Not Confirmed

              Update your events

              Connect Biopharma Initiates Phase 2 Clinical Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis

              Contact the Supplier

              Lead Product(s): CBP-201

              Therapeutic Area: Dermatology Product Name: CBP-201

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 20, 2020

              Details:

              CBP-201 is a novel IL-4Rα antibody that, in a Phase 1b trial, demonstrated an efficacy profile superior to data from clinical studies of the current standard of care therapy for AD after four weeks of treatment.

              PharmaCompass__DigitalAd